title: Cost-Effectiveness of Ofatumumab Plus Chlorambucil in First Line Chronic Lymphocytic Leukemia in Canada.
authors.affiliation: RTI Health Solutions, Research Triangle Park, NC, USA.
authors.forename: W
authors.initials: W
authors.lastname: Herring
authors.affiliation: RTI Health Solutions, Manchester, UK.
authors.forename: I
authors.initials: I
authors.lastname: Pearson
authors.affiliation: RTI Health Solutions, Research Triangle Park, NC, USA.
authors.forename: M
authors.initials: M
authors.lastname: Purser
authors.affiliation: GlaxoSmithKline, Mississauga, ON, Canada.
authors.forename: H R
authors.initials: HR
authors.lastname: Nakhaipour
authors.affiliation: GlaxoSmithKline, Collegeville, PA, USA.
authors.forename: A
authors.initials: A
authors.lastname: Haiderali
authors.affiliation: RTI Health Solutions, Manchester, UK.
authors.forename: S
authors.initials: S
authors.lastname: Wolowacz
authors.affiliation: GlaxoSmithKline, Mississauga, ON, Canada.
authors.forename: K
authors.initials: K
authors.lastname: Jayasundara